Search Results - "Byzova, T.V."

  • Showing 1 - 4 results of 4
Refine Results
  1. 1

    Novel aspects of Kindlin‐3 function in humans based on a new case of leukocyte adhesion deficiency III by MELLER, J., MALININ, N. L., PANIGRAHI, S., KERR, B. A., PATIL, A., MA, Y., VENKATESWARAN, L., ROGOZIN, I. B., MOHANDAS, N., EHLAYEL, M. S., PODREZ, E. A., CHINEN, J., BYZOVA, T. V.

    Published in Journal of thrombosis and haemostasis (01-07-2012)
    “…Background:  Kindlin‐3 is a novel integrin activator in hematopoietic cells, and its deficiency leads to immune problems and severe bleeding, known as…”
    Get full text
    Journal Article
  2. 2

    Platelets govern pre-metastatic tumor communication to bone by Kerr, B A, McCabe, N P, Feng, W, Byzova, T V

    Published in Oncogene (05-09-2013)
    “…Although the survival rate for early detected cancers is high, once a cancer metastasizes to bone, it is incurable. Interestingly, patients without visible…”
    Get full text
    Journal Article
  3. 3

    Safety, inhibition of platelet aggregation and pharmacokinetics of F(ab′) 2 fragments of the anti-glycoprotein IIb-IIIa monoclonal antibody FRaMon in high-risk coronary angioplasty by Mazurov, A.V., Pevzner, D.V., Antonova, O.A., Byzova, T.V., Khaspekova, S.G., Semenov, A.V., Vlasik, T.N., Samko, A.N., Staroverov, I.I., Ruda, M.Ya

    Published in Platelets (Edinburgh) (01-01-2002)
    “…The purpose of the study was to evaluate safety, effects on platelet aggregation and pharmacokinetics of F(ab') 2 fragments of anti-glycoprotein (GP) IIb-IIIa…”
    Get full text
    Journal Article
  4. 4